Elutia (ELUT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
The annual meeting is scheduled for June 11, 2026, with voting available online, by phone, or by mail for shareholders of record as of April 17, 2026.
Key proposals include director elections, auditor ratification, incentive plan amendment, executive compensation approval, and say-on-pay frequency.
The Board recommends voting for all proposals and a one-year frequency for say-on-pay votes.
Voting matters and shareholder proposals
Shareholders will vote on electing two Class III directors for terms expiring in 2029.
Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026 is on the agenda.
Approval sought for the First Amendment to the 2020 Incentive Award Plan, increasing share authorization and extending plan duration.
Advisory votes on executive compensation and the frequency of future say-on-pay votes are included.
Shareholder proposals and director nominations for the 2027 meeting must comply with bylaw deadlines.
Board of directors and corporate governance
The Board consists of five directors divided into three classes, with regular evaluations and a mix of independent and management members.
Board committees include audit, compensation, and nominating/governance, each with defined charters and independent membership.
Corporate Governance Guidelines and a Code of Conduct are in place, with policies on insider trading and anti-hedging.
The Board separates the roles of CEO and Executive Chairman, both currently held by independent directors.
Latest events from Elutia
- Votes will address director elections, auditor ratification, incentive plan, and executive pay.ELUT
Proxy filing23 Apr 2026 - Q4 revenue up 16%, BioEnvelope sale drove debt repayment, and NXT-41x FDA process advanced.ELUT
Q4 202511 Mar 2026 - FDA clearance for EluPro and improved margins offset by a $28.2M net loss in Q2 2024.ELUT
Q2 20242 Feb 2026 - EluPro launches as a biologic alternative in the cardiac device protection market, with full rollout in 2025.ELUT
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - EluPro launches in January, poised to disrupt the $600M pacemaker market with superior technology.ELUT
17th Annual LD Micro Main Event Conference17 Jan 2026 - Q3 net income rose to $1.3M on SimpliDerm growth and EluPro adoption, but risks persist.ELUT
Q3 202414 Jan 2026 - Scaling EluPro adoption and advancing NXT-41X, with strong financial and market momentum.ELUT
Cantor Global Healthcare Conference 202531 Dec 2025 - EluPro's rapid adoption and Boston Scientific partnership fuel growth and improved margins.ELUT
Q4 202424 Dec 2025 - Offering up to $100M in securities, including $50M at-the-market stock, to fund growth amid losses.ELUT
Registration Filing16 Dec 2025